Rui Ma
马睿
Coverage
On the Eve of IPO, a Conversation with METiS Pharmaceuticals' Caida Lai: From Formulas on a Whiteboard to "The SpaceX of Pharma"
The story behind the investment.
峰瑞资本·Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
峰瑞资本·AI for Science Investment and Entrepreneurship: Where Are the Opportunities in the Next Decade?
"That failed data is valuable."
峰瑞资本·AI for Science: Standing at the Turning Point of a Research Paradigm | FreeS Fund Report
What is AI for Science, and why now?
峰瑞资本·Congratulations to XtalPi on its Successful IPO: How FreeS Fund's Research-Driven Approach Learns from Investing
AI + Robotics Creates First 18C Listing — Congratulations to XtalPi
峰瑞资本·Spend a Summer on a VC Journey of "Seeking Truth" and "Taking Things Seriously" | FreeS Fund's 2024 Internship Program Is Now Open
Welcome aboard — a great workplace is one with a bunch of amazing colleagues.
峰瑞资本·FreeS Fund 2023 Year in Review: Take the Long View
In 2024, hold onto hope, keep pushing upward, and do what's right rather than what's easy.
峰瑞资本·What Are Top Overseas Chinese Students Thinking About When It Comes to Entrepreneurship and Investing? | FreeS Fund Dialogue
How do we make sense of the business world and think about the future?
峰瑞资本·FreeS Fund's 8th Anniversary — Welcome Aboard, Let's Go Further Together
Discover more possibilities together.
峰瑞资本·A Debate: Two Investors With Different Perspectives on GPT | FreeS Research Institute
AlphaFold 2 vs. ChatGPT: Which Will Drive Greater Change?
峰瑞资本·Every Brain Is a Unique Little Universe | FreeS Fund's World Autism Awareness Day Special
May every life be treated with gentleness.
峰瑞资本·Conversations with 29 Tech Investors: There Are Treasures, But No Treasure Map
Investing in tech is definitely the right call, but consensus remains scarce.
暗涌Waves·How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
峰瑞资本·The U.S.-China Biotech Race: Where Are the Opportunities in Synthetic Biology? | FreeS Fund Dialogue
Over the next five to ten years, which technologies will have a significant impact on synthetic biology?
峰瑞资本·FreeS Fund's Seventh Anniversary: Working Together to Go Further
Welcome to the team.
峰瑞资本·Untangling the Ins and Outs of Carbon Emissions to Find the Path to Carbon Neutrality | FreeS Research Institute
What Investment Opportunities Exist in the Hundred-Trillion-Yuan Carbon Neutrality Market?
峰瑞资本·How Should We Think About Green Investing? | FreeS Research Institute
Why Does Carbon Neutrality Have to Be Zero?
峰瑞资本·What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
峰瑞资本·What Happens When the Hottest Tech Sectors Collide? | FreeS Fund Chip Series
How do cross-disciplinary ventures that push the boundaries of imagination achieve steady, grounded commercialization?
峰瑞资本·"The Chip Shortage": Entrepreneurial Challenges and Opportunities | FreeS Research Institute · Chip Series
Why Is the Auto Industry Struggling More Than Others With the Chip Shortage?
峰瑞资本·Interdisciplinary Frontier Entrepreneurship: How Chips Are Reshaping Every Industry | May 15 Livestream Registration
See you on May 15!
峰瑞资本·4 Companies Raise Nearly 2 Billion RMB in Total | FreeS Family Funding News · Vol 8
Walk alongside more outstanding founders.
峰瑞资本·How Do Tech Companies Go From "Technology Is Valuable" to "Technology Makes Money"? | FreeS Research --- In the past two years, the tech industry has undergone a profound shift. The era of "technology for technology's sake" is fading. Companies that once commanded sky-high valuations based on technical prowess alone are now facing a harsh reality: investors and markets increasingly demand proof that technology can translate into sustainable profits. This transition—from "technology is valuable" to "technology makes money"—is far from automatic. It requires fundamental changes in how tech companies think about product-market fit, commercialization strategy, and organizational capabilities. ## The Valuation Trap For years, Chinese tech companies were rewarded for technical milestones. Breakthroughs in AI, quantum computing, or autonomous driving could attract hundreds of millions in funding before a single revenue dollar was earned. The underlying assumption: superior technology would inevitably find commercial applications. This logic has collapsed on multiple fronts. Some technologies proved to be solutions in search of problems. Others faced regulatory headwinds that made their intended business models unviable. Still others discovered that the cost of commercial deployment far exceeded initial projections, rendering unit economics untenable. The result is a growing cohort of "zombie unicorns
Why should tech talent avoid "walking around with a hammer looking for nails"?
峰瑞资本·FreeS Fund Earns Ten Honors from Zero2IPO, PEDaily, ChinaVenture & GEW, CVCRI, ChinaRong360, Wanbang RB, and Lancha Consumer | FreeS Matters
Continuously hiring investors
峰瑞资本·Going live tonight at 8:30 PM | A conversation on opportunities and trends in the brain science industry
See you at 8:30 tonight.
峰瑞资本·FreeS Report 24 | Embracing the "Smartest" Opportunity: Investing Boldly in Brain and Neuroscience
If the universe is complex, mysterious, and captivating, so is the brain.
峰瑞资本·Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
峰瑞资本·Celebrating Six Years, Looking Forward to More Upward-Minded Partners Joining Us | FreeS Fund
Do what's right, not what's easy.
峰瑞资本·What's It Like Doing Venture Capital in China? | 2021 FreeS Fund China-US VC Forum Transcript
How do you know if you're cut out for investing? What challenges will you face along the way?
峰瑞资本·Li Feng: Will Consumer Investment Stay Hot in 2021? | FreeS Research
Whenever most people aren't optimistic, there's usually an opportunity hiding in there.
峰瑞资本·FreeS Fund China-US Venture Forum Session 2 is still open for registration; FreeS Fund receives multiple recognitions from Langchao New Consumption, Joy Capital, and Qiming Technology & New Voice Innovation Service
Do what's right, not what's easy.
峰瑞资本·FreeS Fund China-US Venture Capital Forum Registration Now Open | Seizing New Opportunities in China's Era
Whether you're looking for a job or starting a company, feel free to come chat with us at FreeS Fund.
峰瑞资本·Wang Liming: Another Breakthrough in AI Protein Structure Prediction — What Does It Mean?
Brute force makes miracles?
峰瑞资本·Why Is AI Drug Discovery So Hot, and Why Now? | FreeS Fund Biomedical VC Summit Transcript
Why We're Bullish on AI Drug Discovery
峰瑞资本·Why Is AI Drug Discovery So Hot? And How Long Will It Stay Hot? | FreeS Fund Events & Research Recs
Three Slightly Brain-Burning Little Gifts
峰瑞资本·A Job Posting, Three Events | Frees Fund
Looking forward to your participation.
峰瑞资本·FreeS Fund Healthcare Open Day Is Here: Entering the Grand Era of Biomedical Innovation
Looking for China's Genentech, Moderna, Alnylam, Spark, Nimbus Therapeutics
峰瑞资本·Brain Diseases in Its Crosshairs: NeuroXess Raises $4.2 Million in Angel Round | FreeS Fund Deal News
Brain research remains one of the great unsolved challenges in science.
峰瑞资本·IPOs, Top 50 Best Returns, New Breakthroughs in Rocket Technology... 23 Milestones and 11 Reflections | FreeS Fund Blackboard · July
Do what's right, not what's easy.
峰瑞资本·FreeS Fund Sets Up Shop in Shanghai, New Office Now Operational
FreeS Fund opens offices in both the north and south, choosing to do what's right rather than what's easy.
峰瑞资本·The Birth of a Retail Unicorn, Winning the Championship, and Finding the "Nail"... 12 Advances and 3 Insights | FreeS Fund Blackboard · October
Continuing to Push on Consumer and Deep Tech
峰瑞资本·XtalPi Closes $46 Million Series B+ Round | FreeS Fund Deal Brief
Empowering drug R&D organizations worldwide.
峰瑞资本·Bluepha Completes Pre-A Round, Angel Investor FreeS Fund Continues to Follow On | FreeS Fund Investment News
Create more microbes to fully satisfy people's pursuit of a better life.
峰瑞资本·
